AEON Biopharma, Inc. — Form 8-K Summary
Reporting period and business context: The filing reports a change in the independent registered public accounting firm for AEON Biopharma Sub, Inc., the Company’s operating subsidiary. The audit committee dismissed Ernst & Young LLP (“EY”) effective September 28, 2023, and approved KPMG LLP as the new auditor for the fiscal year ending December 31, 2023. The Form 8-K was signed and filed on October 2, 2023.
Financial and Operating Information
- EY’s audit reports for the fiscal years ended December 31, 2022 and 2021 did not contain an adverse opinion or disclaimer of opinion.
- EY’s reports included an explanatory paragraph regarding the Operating Company’s ability to continue as a going concern.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, cash balance, or other quantitative financial metrics.
Material Changes Versus Prior Period
- EY was replaced by KPMG as the Company’s independent registered public accounting firm.
- The Company stated that the auditor change was not the result of any disagreement with EY.
- For fiscal years 2022 and 2021 and the interim period through September 28, 2023, the Company reported no disagreements with EY regarding accounting principles, financial statement disclosures, or audit scope and procedures.
- The Company also reported no reportable events related to EY during the applicable periods.
Outlook, Risks, and Unusual Items
- The going-concern explanatory paragraph in EY’s prior audit reports is a material risk indicator; the filing does not provide additional detail on the underlying circumstances or the Company’s remediation plans.
- The filing contains no management financial guidance or operating forecast.
- KPMG was not consulted during the prior periods regarding accounting principles for a specified transaction, the type of audit opinion, disagreements, or reportable events.
- EY’s letter regarding the auditor change, dated October 2, 2023, was included as Exhibit 16.1.
Important Facts to Verify
- Review the underlying 2021 and 2022 financial statements and EY’s going-concern disclosures.
- Assess whether the auditor transition affects the timing, scope, or conclusions of the 2023 audit.
- Review EY’s Exhibit 16.1 letter for any comments regarding the Company’s disclosures.
- Verify the Company’s current cash resources, financing arrangements, debt obligations, and liquidity plans, which are not quantified in this filing.